B12 level reference ranges Troubleshooting common problems Things do not always go according to the chart
N Engl J Med (2021) 385(10):896907
Clinical study observations suggest that treatment with oral GLC in combination with UVB improves active generalized vitiligo (Mou et al., 2016)
Post-hoc analysis of SUSTAIN-6 (semaglutide sc.) showed the same results as those obtained in post-hoc analysis of LEADER (liraglutide sc.) in terms of MACE reduction, despite the presence or otherwise of previous microvascular disease (although this enhances the chances of a MACE) [56] and blood pressure levels [55]
adults with overweight or obesity
Titration schedule of Rybelsus is as follows: Formulation R1 (3 mg, 7 mg, 14 mg) Weeks 14 (Days 130): 3 mg once daily (This is the starting dose that may not be effective for glycemic control) Weeks 58 (Days 3160): 7 mg once daily Weeks 9 and onwards (Day 61+): Maintain 7 mg once daily if adequate control is achieved Increase to 14 mg once daily if additional glycemic control needed Formulation R2 (1.5 mg, 4 mg, 9 mg) Week 14 (Days 130): 1.5 mg once daily Week 58 (Days 3160): 4 mg once daily Week 9 onward (Day 61+): Maintain 4 mg once daily if adequate control is achieved or, Increase to 9 mg once daily if additional glycemic control is needed Why a conversion chart matters Liraglutide, semaglutide, and dulaglutide are GLP-1 agonists, but they have different active ingredients, indications, efficacy, and potencies
